Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.12M in total
- 2
- 13F holdersQ2 2026, +22 vs. previous quarter
- 231
- 13F valueReported value at the end of Q2 2026
- $3.78B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RCUS, Q2 2026
No superinvestor reported holding RCUS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Arcus Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 (view filing)5:52 PM ET | Aug 21 | 3 days | Azoy AlexanderChief Accounting Officer | SSale | −2.83K | $30.00 | −$84.8K | −6.7%39.6K after | 10b5-1 |
| Jul 13, 2026 (view filing)5:36 PM ET | Jul 9-10 | 4 days | Jaen Juan C.President | SSale | −68.6K | $29.63 | −$2.03M | −7.7%822.2K after | 3 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22-24 | 2 days | Jaen Juan C.President | SSale | −31.4K | $27.92 | −$877.5K | −3.4%890.8K after | 4 lots10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Azoy AlexanderChief Accounting Officer | SSale | −2.56K | $25.77 | −$66.0K | −6.1%39.6K after | 10b5-1 |
| May 12, 2026 (view filing) | May 11 | 1 day | Goeltz II Robert C.Chief Financial Officer | SSale | −7.76K | $25.63 | −$199.0K | −8.4%84.2K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Jaen Juan C.President | SSale | −31.8K | $21.41 | −$681.3K | −3.3%922.2K after | 3 lots10b5-1 |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Goeltz II Robert C.Chief Financial Officer | SSale | −6.55K | $23.38 | −$153.2K | −8.8%67.9K after | 10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Markus RichardChief Medical Officer | SSale | −9.55K | $22.01 | −$210.1K | −12.7%65.6K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Tang Carolyn C.General Counsel | SSale | −14.5K | $22.01 | −$318.5K | −10.4%124.7K after | 2 lots10b5-1 |
| Dec 18, 2025 (view filing) | Dec 16-18 | 2 days | Azoy AlexanderChief Accounting Officer | SSale | −8.83K | $22.13 | −$195.4K | −32.3%18.5K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Arcus Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | $968.8M | 58.76% | 00.0% | Unchanged |
| BlackRock, Inc. | 16,416,249 | $506.1M | 0.01% | +1,189,774+7.8% | Added |
| State Street Corp | 6,029,484 | $185.9M | 0.01% | +616,583+11.4% | Added |
| Wellington Management Group LLP | 5,895,448 | $181.8M | 0.03% | −194,068−3.2% | Reduced |
| Suvretta Capital Management, LLC | 4,776,423 | $147.3M | 3.09% | −254,570−5.1% | Reduced |
| Vanguard Portfolio Management LLC | 4,475,528 | $138.0M | 0.01% | +203,472+4.8% | Added |
| FMR LLC | 4,049,757 | $124.9M | 0.01% | +2,884,505+247.5% | Added |
| Vanguard Capital Management LLC | 3,888,346 | $119.9M | 0.00% | +31,621+0.8% | Added |
| Citadel Advisors LLC | 3,135,057 | $96.7M | 0.06% | +1,805,122+135.7% | Added |
| Woodline Partners LP | 3,007,798 | $92.7M | 0.29% | −770,000−20.4% | Reduced |